

VIA ELECTRONIC MAIL

To: Vermont Attorney General's Office

Address: 109 State Street Montpelier, VT 05609

Email: AGO.highcostprescriptiondrugs@vermont.gov

Subject: Solubiomix LLC - New Drug Notice

Date: 4/18/2024

To Whom It May Concern:

As required by 18 V.S.A. § 4637(b), Solubiomix LLC is providing notice of the introduction of new prescription drugs with a wholesale acquisition cost which exceeds the specialty drug threshold under the Medicare Part D program:

NDC	Description	Brand/Generic	Strength	WAC	Launch Date
69499-0403-60	Oxaprozin Oral Capsule 60ct 300mg	Trade	300 mg	2573.5	4/15/2024
73308-0403-60	Oxaprozin Capsule 60ct 300mg	Generic	300 mg	2098.54	4/15/2024

The information regarding the description of the marketing and pricing plans used in the launch of the above new drugs in the United States and internationally is considered proprietary. We do not have an estimate of the number of patients who may be prescribed the drug in Vermont. Neither drug was granted breakthrough therapy designation or priority review by the FDA prior to final approval.

If any other information is required, please let us know.

Thanks,

Kenquavius McCollum